HCM
EBS icon

Herndon Capital Management’s Emergent Biosolutions EBS Stock Holding History

Herndon Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$3K Buy
+100
New +$3.09K ﹤0.01% 189

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AAM
Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.79B AUM 33.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Herndon Capital Management's EBS Position: Q2 2017 in Review

Herndon Capital Management opened a new position in Emergent Biosolutions (EBS) in Q2 2017: 100 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #189 among its holdings.

181 funds tracked by Wall St. Rank hold EBS as of Q2 2017.

  • Herndon Capital Management held 100 shares of Emergent Biosolutions worth $3K as of Q2 2017.
  • Emergent Biosolutions was a new Herndon Capital Management position in Q2 2017.
  • Emergent Biosolutions made up ﹤0.01% of Herndon Capital Management's portfolio in Q2 2017, its #189 holding.
  • 181 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2017.

Based on Herndon Capital Management's 13F filing for Q2 2017, filed 4 Aug 2017.